Lorecivivint

N/A

Report date: 2026/01/07 17:52:52
NME

Base Information

Drug NameLorecivivint
Drug Alias NameAdavivintSM-04690
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionWnt signalling pathway inhibitorsDual specificity protein kinase CLK2 inhibitorsDual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors
TargetsDual specificity protein kinase CLK2Dual-specificity tyrosine-phosphorylation regulated kinase 1A
Therapy Area/IndicationsOsteoarthritis, KneeOsteoarthritisIntervertebral Disc Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesBiosplice Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSamil Pharmaceutical Co LtdBiosplice Therapeutics IncHaisco Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsOsteoarthritis, Knee
Inactive IndicationsOsteoarthritisIntervertebral Disc Degeneration

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG